These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 26845715)

  • 1. Oral propranolol in early stages of retinopathy of prematurity.
    Bancalari A; Schade R; Muñoz T; Lazcano C; Parada R; Peña R
    J Perinat Med; 2016 Jul; 44(5):499-503. PubMed ID: 26845715
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The efficacy of propranolol in very preterm infants at the risk of retinopathy of prematurity: Which newborn and when?
    Ozturk MA; Korkmaz L
    Int Ophthalmol; 2019 Sep; 39(9):1921-1930. PubMed ID: 30229439
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of intravitreal bevacizumab for zone-II retinopathy of prematurity.
    Karkhaneh R; Khodabande A; Riazi-Eafahani M; Roohipoor R; Ghassemi F; Imani M; Dastjani Farahani A; Ebrahimi Adib N; Torabi H
    Acta Ophthalmol; 2016 Sep; 94(6):e417-20. PubMed ID: 27009449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Update in the Treatment of Retinopathy of Prematurity.
    Bancalari A; Schade R
    Am J Perinatol; 2022 Jan; 39(1):22-30. PubMed ID: 32544962
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral propranolol for prevention of threshold retinopathy of prematurity (ROPROP): protocol of a randomised controlled trial.
    Bührer C; Erdeve Ö; Bassler D; Bar-Oz B
    BMJ Open; 2018 Jul; 8(7):e021749. PubMed ID: 29982217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral propranolol for retinopathy of prematurity: risks, safety concerns, and perspectives.
    Filippi L; Cavallaro G; Bagnoli P; Dal Monte M; Fiorini P; Donzelli G; Tinelli F; Araimo G; Cristofori G; la Marca G; Della Bona ML; La Torre A; Fortunato P; Furlanetto S; Osnaghi S; Mosca F
    J Pediatr; 2013 Dec; 163(6):1570-1577.e6. PubMed ID: 24054431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Study protocol: safety and efficacy of propranolol in newborns with Retinopathy of Prematurity (PROP-ROP): ISRCTN18523491.
    Filippi L; Cavallaro G; Fiorini P; Daniotti M; Benedetti V; Cristofori G; Araimo G; Ramenghi L; La Torre A; Fortunato P; Pollazzi L; la Marca G; Malvagia S; Bagnoli P; Ristori C; Dal Monte M; Bilia AR; Isacchi B; Furlanetto S; Tinelli F; Cioni G; Donzelli G; Osnaghi S; Mosca F
    BMC Pediatr; 2010 Nov; 10():83. PubMed ID: 21087499
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes after Intravitreal Bevacizumab versus Laser Photocoagulation for Retinopathy of Prematurity: A 5-Year Retrospective Analysis.
    Hwang CK; Hubbard GB; Hutchinson AK; Lambert SR
    Ophthalmology; 2015 May; 122(5):1008-15. PubMed ID: 25687024
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effects of intravitreal pegaptanib or bevacizumab and laser in treatment of threshold retinopathy of prematurity in zone I and posterior zone II--four years results].
    Autrata R; Senková K; Holousová M; Krejcírová I; Dolezel Z; Borek I
    Cesk Slov Oftalmol; 2012 Feb; 68(1):29-36. PubMed ID: 22679695
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral propranolol in prevention of severe retinopathy of prematurity: a systematic review and meta-analysis.
    Stritzke A; Kabra N; Kaur S; Robertson HL; Lodha A
    J Perinatol; 2019 Dec; 39(12):1584-1594. PubMed ID: 31570797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Study protocol: safety and efficacy of propranolol 0.2% eye drops in newborns with a precocious stage of retinopathy of prematurity (DROP-ROP-0.2%): a multicenter, open-label, single arm, phase II trial.
    Filippi L; Cavallaro G; Berti E; Padrini L; Araimo G; Regiroli G; Bozzetti V; De Angelis C; Tagliabue P; Tomasini B; Buonocore G; Agosti M; Bossi A; Chirico G; Aversa S; Pasqualetti R; Fortunato P; Osnaghi S; Cavallotti B; Vanni M; Borsari G; Donati S; Nascimbeni G; la Marca G; Forni G; Milani S; Cortinovis I; Bagnoli P; Dal Monte M; Calvani AM; Pugi A; Villamor E; Donzelli G; Mosca F
    BMC Pediatr; 2017 Jul; 17(1):165. PubMed ID: 28709412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Refractive Error in Patients with Retinopathy of Prematurity after Laser Photocoagulation or Bevacizumab Monotherapy.
    Kuo HK; Sun IT; Chung MY; Chen YH
    Ophthalmologica; 2015; 234(4):211-7. PubMed ID: 26393895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. OUTCOMES AFTER LASER VERSUS COMBINED LASER AND BEVACIZUMAB TREATMENT FOR TYPE 1 RETINOPATHY OF PREMATURITY IN ZONE I.
    Yoon JM; Shin DH; Kim SJ; Ham DI; Kang SW; Chang YS; Park WS
    Retina; 2017 Jan; 37(1):88-96. PubMed ID: 27347645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Efficacy of Propranolol in Retinopathy of Prematurity and its Correlation with the Platelet Mass Index.
    Korkmaz L; Baştuğ O; Ozdemir A; Korkut S; Karaca C; Akin MA; Gunes T; Kurtoglu S; Ozturk MA
    Curr Eye Res; 2017 Jan; 42(1):88-97. PubMed ID: 27260268
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral Propranolol: A New Treatment for Infants with Retinopathy of Prematurity?
    Bührer C; Bassler D
    Neonatology; 2015; 108(1):49-52. PubMed ID: 25968340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Retinopathy of the premature: Update in screening and treatment].
    Bancalari M A; Schade R
    Rev Chil Pediatr; 2020 Feb; 91(1):122-130. PubMed ID: 32730423
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravitreal Bevacizumab for Zone II Retinopathy of Prematurity.
    Larrañaga-Fragoso P; Peralta J; Bravo-Ljubetic L; Pastora N; Abelairas-Gómez J
    J Pediatr Ophthalmol Strabismus; 2016 Nov; 53(6):375-382. PubMed ID: 27537247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of Plasma Cytokine Profile Changes in Bevacizumab-Treated Retinopathy of Prematurity Infants.
    Kong L; Demny AB; Sajjad A; Bhatt AR; Devaraj S
    Invest Ophthalmol Vis Sci; 2016 Apr; 57(4):1649-54. PubMed ID: 27054517
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combine intravitreal bevacizumab injection with laser treatment for aggressive posterior retinopathy of prematurity (AP-ROP).
    Wutthiworawong B; Thitiratsanont U; Saovaprut C; Subhangkasen I; Geyuraphun B; Ampornprut A; Phumongkutchai J; Tephusdinnaayuthaya S
    J Med Assoc Thai; 2011 Aug; 94 Suppl 3():S15-21. PubMed ID: 22043749
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravitreal bevacizumab for retinopathy of prematurity: refractive error results.
    Harder BC; Schlichtenbrede FC; von Baltz S; Jendritza W; Jendritza B; Jonas JB
    Am J Ophthalmol; 2013 Jun; 155(6):1119-1124.e1. PubMed ID: 23490192
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.